Domestic drugs reach record high share of public procurements in Russia

25 March 2019

The share of domestic drugs in the public procurements in Russia has reached record figures for the last four years and currently continues to grow, according to recent statistics, published by the Russian Ministry of Health and statements of some local analysts in the field of pharmaceutics.

The published statistics show that the share of domestically-made drugs in the segment of public procurements in Russia during the period of 2014–2018 grew from 20% to 35% in value terms, reports The Pharma Letter’s local correspondent.

According to data from DSM Group, in value terms these figures grew from 66.5 billion roubles ($1 billion) in 2014 to 148.7 billion roubles in 2018.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK